Lineage Cell Therapeutics (LCTX) Non Operating Income (2010 - 2026)
Lineage Cell Therapeutics (LCTX) reported Non Operating Income of $1000.0 for Q1 2026, up 100.54% on a YoY basis from $498.65 in Q1 2025, and up 100.02% quarter-over-quarter from -$4.9 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Non Operating Income (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Non Operating Income for 17 years, with the latest figure at $1000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 100.54% year-over-year to $1000.0; the trailing twelve-month figure through Mar 2026 stood at -$15.5 million (down 692.52% YoY), and the FY2025 full-year result was -$5.0 million, down 273.65% from the prior year.
- Non Operating Income for Q1 2026 stood at $1000.0, up from -$4.9 million in the prior quarter.
- The five-year high for Non Operating Income was $1.9 million in Q4 2024, with the low at -$10.6 million in Q2 2025.
- Historically, Non Operating Income has averaged -$785062.5 across 5 years, with a median of $1000.0 in 2023.
- Annual changes were most pronounced in 2024 — Non Operating Income surged 83800.0% — and 2025, when it tumbled 11359.57%.
- Lineage Cell Therapeutics' Non Operating Income stood at $1.4 million in 2022, then sank by 35.99% to $907000.0 in 2023, then jumped by 105.07% to $1.9 million in 2024, then sank by 361.83% to -$4.9 million in 2025, then jumped by 100.02% to $1000.0 in 2026.
- The last three Non Operating Income figures came in at $1000.0 (Q1 2026), -$4.9 million (Q4 2025), and -$10.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | 1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | -4.87 Mn |
| Jun 30, 2025 | -10.58 Mn |
| Mar 31, 2025 | -185,000.00 |
| Dec 31, 2024 | 1.86 Mn |
| Sep 30, 2024 | 839,000.00 |
| Jun 30, 2024 | 94,000.00 |
| Mar 31, 2024 | 103,000.00 |
| Dec 31, 2023 | 907,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | -179,000.00 |
| Mar 31, 2023 | 435,000.00 |
| Dec 31, 2022 | 1.42 Mn |
| Sep 30, 2022 | -324,000.00 |
| Jun 30, 2022 | -1.89 Mn |
| Mar 31, 2022 | -184,000.00 |
| Dec 31, 2021 | 1.80 Mn |
| Sep 30, 2021 | 393,000.00 |
| Jun 30, 2021 | 970,000.00 |
| Mar 31, 2021 | -1.68 Mn |